Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, efficacy, and tolerability of IDP-123 Lotion in comparison with IDP-123 Vehicle Lotion.
This is a multi-center, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, efficacy, and tolerability of IDP-123 Lotion and IDP-123 Vehicle Lotion. To be eligible for the study subjects must be at least 9 years of age and have a clinical diagnosis of moderate to severe acne.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| IDP-123 Lotion | Experimental | Tazarotene 0.045% Lotion |
|
| IDP-123 Vehicle Lotion | Placebo Comparator | Vehicle Lotion |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| IDP-123 Lotion | Drug | Tazarotene 0.045% Lotion |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Absolute Change in Mean Lesion Counts at Week 12 | For noninflammatory facial lesions, open comedones (blackheads) and closed comedones (whiteheads) were recorded as a single count. For inflammatory facial lesions, papules (solid, elevated lesion less than 5 mm) and pustules (elevated lesion containing pus less than 5 mm) were recorded as a single count, while nodular lesions (palpable subcutaneous lesion greater than 5 mm) were counted and recorded separately. | Baseline to Week 12 |
| Percentage of Subjects Who Had at Least a 2-grade Reduction From Baseline at Week 12 in the Evaluator's Global Severity Score (EGSS) and Had an EGSS at Week 12 That Equated to "Clear" or "Almost Clear" | Evaluator's Global Severity Score (EGSS) was determined based on evaluator-blinded evaluations of the signs and symptoms of acne vulgaris. Evaluations were scored on a scale of 0-4, with 0 being clear and 4 being severe. | Baseline to Week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage Change in Mean Lesion Counts at Week 12 | For noninflammatory facial lesions, open comedones (blackheads) and closed comedones (whiteheads) were recorded as a single count. For inflammatory facial lesions, papules (solid, elevated lesion less than 5 mm) and pustules (elevated lesion containing pus less than 5 mm) were recorded as a single count, while nodular lesions (palpable subcutaneous lesion greater than 5 mm) were counted and recorded separately. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Anya Loncaric | Valeant Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Valeant Site 19 | Phoenix | Arizona | 85032 | United States | ||
| Valeant Site 21 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | IDP-123 Lotion | IDP-123 (Tazarotene 0.045%) Lotion |
| FG001 | Vehicle Lotion | IDP-123 Vehicle Lotion |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Aug 24, 2017 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| IDP-123 Vehicle Lotion | Drug | Vehicle Lotion |
|
|
| Baseline to Week 12 |
| Percentage of Subjects Who Had at Least a 2-grade Reduction From Baseline at Week 12 in the Evaluator's Global Severity Score (EGSS) | Evaluator's Global Severity Score (EGSS) was determined based on evaluator-blinded evaluations of the signs and symptoms of acne vulgaris. Evaluations were scored on a scale of 0-4, with 0 being clear and 4 being severe. | Baseline to Week 12 |
| Percentage Change in Mean Lesion Counts at Week 8 | For noninflammatory facial lesions, open comedones (blackheads) and closed comedones (whiteheads) were recorded as a single count. For inflammatory facial lesions, papules (solid, elevated lesion less than 5 mm) and pustules (elevated lesion containing pus less than 5 mm) were recorded as a single count, while nodular lesions (palpable subcutaneous lesion greater than 5 mm) were counted and recorded separately. | Baseline to Week 8 |
| Percentage Change in Mean Lesion Counts at Week 4 | For noninflammatory facial lesions, open comedones (blackheads) and closed comedones (whiteheads) were recorded as a single count. For inflammatory facial lesions, papules (solid, elevated lesion less than 5 mm) and pustules (elevated lesion containing pus less than 5 mm) were recorded as a single count, while nodular lesions (palpable subcutaneous lesion greater than 5 mm) were counted and recorded separately. | Baseline to Week 4 |
| Phoenix |
| Arizona |
| 85032 |
| United States |
| Valeant Site 24 | Hot Springs | Arkansas | 71913 | United States |
| Valeant Site 04 | La Mesa | California | 91942 | United States |
| Valeant Site 02 | Manhattan Beach | California | 90266 | United States |
| Valeant Site 42 | Murrieta | California | 92562 | United States |
| Valeant Site 39 | Sacramento | California | 95819 | United States |
| Valeant Site 01 | San Diego | California | 22434 | United States |
| Valeant Site 37 | Wheat Ridge | Colorado | 80033 | United States |
| Valeant Site 35 | Boca Raton | Florida | 33486 | United States |
| Valeant Site 40 | North Miami Beach | Florida | 33162 | United States |
| Valeant Site 33 | Ormond Beach | Florida | 32174 | United States |
| Valeant Site 27 | Pembroke Pines | Florida | 33028 | United States |
| Valeant Site 13 | Sanford | Florida | 32771 | United States |
| Valeant Site 03 | West Palm Beach | Florida | 33401 | United States |
| Valeant Site 26 | Newnan | Georgia | 30263 | United States |
| Valeant Site 30 | Boise | Idaho | 83704 | United States |
| Valeant Site 06 | Arlington Heights | Illinois | 60005 | United States |
| Valeant Site 23 | New Albany | Indiana | 47150 | United States |
| Valeant Site 17 | South Bend | Indiana | 46617 | United States |
| Valeant Site 31 | Overland Park | Kansas | 66215 | United States |
| Valeant Site 22 | Louisville | Kentucky | 40217 | United States |
| Valeant Site 08 | Metairie | Louisiana | 70006 | United States |
| Valeant Site 38 | Detroit | Michigan | 48202 | United States |
| Valeant Site 16 | Warren | Michigan | 48088 | United States |
| Valeant site 20 | New York | New York | 10022 | United States |
| Valeant Site 36 | New York | New York | 10075 | United States |
| Valeant Site 09 | High Point | North Carolina | 27262 | United States |
| Valeant Site 32 | Cincinnati | Ohio | 45236 | United States |
| Valeant Site 11 | Dublin | Ohio | 43016 | United States |
| valeant Site 07 | Gresham | Oregon | 97030 | United States |
| Valeant Site 15 | Johnston | Rhode Island | 02919 | United States |
| Valeant Site 34 | Knoxville | Tennessee | 37917 | United States |
| valeant Site 14 | Nashville | Tennessee | 37215 | United States |
| Valeant Site 12 | Austin | Texas | 78759 | United States |
| Valeant Site 05 | Katy | Texas | 77494 | United States |
| Valeant Site 18 | Plano | Texas | 75093 | United States |
| Valeant Site 25 | San Antonio | Texas | 78213 | United States |
| Valeant Site 43 | Webster | Texas | 77598 | United States |
| Valeant Site 41 | Salt Lake City | Utah | 84114 | United States |
| Valeant Site 45 | Norfolk | Virginia | 23507 | United States |
| Valeant Site 44 | Spokane | Washington | 99202 | United States |
| Valeant Site 29 | Peterborough | Ontario | K9J5K2 | Canada |
| Valeant Site 28 | Waterloo | Ontario | N2J1C4 | Canada |
| Valeant Site 10 | Laval | Quebec | H7E0E3 | Canada |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | IDP-123 Lotion | IDP-123 (Tazarotene 0.045%) Lotion |
| BG001 | Vehicle Lotion | IDP-123 Vehicle Lotion |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Lesion counts | For noninflammatory facial lesions, open comedones (blackheads) and closed comedones (whiteheads) were recorded as a single count. For inflammatory facial lesions, papules (solid, elevated lesion less than 5 mm) and pustules (elevated lesion containing pus less than 5 mm) were recorded as a single count, while nodular lesions (palpable subcutaneous lesion greater than 5 mm) were counted and recorded separately. | Mean | Standard Deviation | lesions |
| ||||||||||||||
| Evaluator's Global Severity Score | Evaluator's Global Severity Score (EGSS) was determined based on evaluator-blinded evaluations of the signs and symptoms of acne vulgaris. Evaluations were scored on a scale of 0-4, with 0 being clear and 4 being severe. | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Absolute Change in Mean Lesion Counts at Week 12 | For noninflammatory facial lesions, open comedones (blackheads) and closed comedones (whiteheads) were recorded as a single count. For inflammatory facial lesions, papules (solid, elevated lesion less than 5 mm) and pustules (elevated lesion containing pus less than 5 mm) were recorded as a single count, while nodular lesions (palpable subcutaneous lesion greater than 5 mm) were counted and recorded separately. | Posted | Least Squares Mean | Standard Deviation | lesion counts | Baseline to Week 12 |
|
|
| ||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Subjects Who Had at Least a 2-grade Reduction From Baseline at Week 12 in the Evaluator's Global Severity Score (EGSS) and Had an EGSS at Week 12 That Equated to "Clear" or "Almost Clear" | Evaluator's Global Severity Score (EGSS) was determined based on evaluator-blinded evaluations of the signs and symptoms of acne vulgaris. Evaluations were scored on a scale of 0-4, with 0 being clear and 4 being severe. | Posted | Number | percentage of participants | Baseline to Week 12 |
|
| ||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage Change in Mean Lesion Counts at Week 12 | For noninflammatory facial lesions, open comedones (blackheads) and closed comedones (whiteheads) were recorded as a single count. For inflammatory facial lesions, papules (solid, elevated lesion less than 5 mm) and pustules (elevated lesion containing pus less than 5 mm) were recorded as a single count, while nodular lesions (palpable subcutaneous lesion greater than 5 mm) were counted and recorded separately. | Posted | Least Squares Mean | Standard Deviation | percentage change | Baseline to Week 12 |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Subjects Who Had at Least a 2-grade Reduction From Baseline at Week 12 in the Evaluator's Global Severity Score (EGSS) | Evaluator's Global Severity Score (EGSS) was determined based on evaluator-blinded evaluations of the signs and symptoms of acne vulgaris. Evaluations were scored on a scale of 0-4, with 0 being clear and 4 being severe. | Posted | Number | percentage of participants | Baseline to Week 12 |
|
| ||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage Change in Mean Lesion Counts at Week 8 | For noninflammatory facial lesions, open comedones (blackheads) and closed comedones (whiteheads) were recorded as a single count. For inflammatory facial lesions, papules (solid, elevated lesion less than 5 mm) and pustules (elevated lesion containing pus less than 5 mm) were recorded as a single count, while nodular lesions (palpable subcutaneous lesion greater than 5 mm) were counted and recorded separately. | Posted | Least Squares Mean | Standard Deviation | percentage change | Baseline to Week 8 |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Percentage Change in Mean Lesion Counts at Week 4 | For noninflammatory facial lesions, open comedones (blackheads) and closed comedones (whiteheads) were recorded as a single count. For inflammatory facial lesions, papules (solid, elevated lesion less than 5 mm) and pustules (elevated lesion containing pus less than 5 mm) were recorded as a single count, while nodular lesions (palpable subcutaneous lesion greater than 5 mm) were counted and recorded separately. | Posted | Least Squares Mean | Standard Deviation | percentage change | Baseline to Week 4 |
|
|
12 weeks
Safety population included all participants who received at least one confirmed dose of study drug and had at least one post-baseline safety assessment. There were 10 participants in the IDP-123 Lotion and 12 participants in the IDP-123 Vehicle Lotion group who did not have any post-baseline safety assessment.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | IDP-123 Lotion | IDP-123 (Tazarotene 0.045%) Lotion | 0 | 392 | 3 | 392 | 0 | 392 |
| EG001 | Vehicle Lotion | IDP-123 Vehicle Lotion | 0 | 399 | 3 | 399 | 0 | 399 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abortion induced | Surgical and medical procedures | MedDRA (20.0) | Non-systematic Assessment |
| |
| Abortion spontaneous | Surgical and medical procedures | MedDRA (20.0) | Non-systematic Assessment |
| |
| Suicidal ideation | Psychiatric disorders | MedDRA (20.0) | Non-systematic Assessment |
| |
| Appendicitis | Infections and infestations | MedDRA (20.0) | Non-systematic Assessment |
| |
| Rhabdomyolysis | Musculoskeletal and connective tissue disorders | MedDRA (20.0) | Non-systematic Assessment |
|
Not provided
Please contact Sponsor directly for additional information.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Study Director | Bausch Health Americas, Inc | 510-259-5284 | aloncaric@bauschhealth.com |
| Feb 15, 2021 |
| Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D000152 | Acne Vulgaris |
| ID | Term |
|---|---|
| D017486 | Acneiform Eruptions |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D012625 | Sebaceous Gland Diseases |
Not provided
Not provided
| Male |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Inflammatory lesions |
|
| Severe |
|
|
|
|
|
|